Johnson & Johnson Vision announced that it received approval in Japan for its Acuvue Theravision lens with Ketotifen. The company touts the lens as the first and only vision-correcting contact lens that relieves allergic eye itch through drug delivery, according to a news release. Japan’s Ministry of Health, Labour and Welfare (MHLW) approved the lens, […]
Eyenovia partners with Eversana to commercialize pupil dilation agent
Eyenovia (NSDQ:EYEN) announced today that it partnered with Eversana to help commercialize MydCombi if it earns U.S. approval. MydCombi is a fixed-combination mydriatic agent for potential use in comprehensive eye exams with a formulation for touchless fixed-combination microdosing in an effort to improve the patient experience. The FDA earlier this month accepted Eyenovia’s New Drug […]
Research indicates notable future growth in transdermal patch market
Research published today has highlighted potential growth down the line in the transdermal drug delivery patch space. Kuick Research published an analysis claiming that the U.S. transdermal patch drug market is revolving on account of two powerful “mega-trends.” Those trends — acceleration in the U.S. pharmaceutical market growth and the restructuring of the healthcare sector […]
Fractyl enrolls first patient in Revita DMR treatment for Type 2 diabetes
Fractyl Laboratories announced today that it enrolled the first patient in the trial for its Revita DMR Type 2 diabetes treatment. The Revita-T2Di trial will evaluate a single Revita DMR treatment to allow patients currently on insulin therapy but with inadequate glycemic control to achieve durable insulin-free glycemic control. The company will seek to use […]
BioCorp, Diabeloop partner on diabetes management tech development
BioCorp and Diabeloop announced today that they are entering a cooperation agreement to develop new personalized diabetes treatments. Diabeloop develops automated insulin delivery (AID) systems, including a self-learning algorithm hosted in a handset and connected to a continuous glucose monitoring (CGM) system and an insulin pump. The platform analyzes glucose data, calculates the right dose […]
Insulet touts results from Omnipod 5 study, expects launch this year
Insulet (NSDQ:PODD) touted positive results from the first pivotal trial for its Omnipod 5 automated insulin delivery system. Omnipod 5 is the world’s first tubeless, wearable system designed to continuously adapt insulin delivery based on glucose levels and trends, according to a news release. Acton, Mass.-based Insulet said the device, which has FDA breakthrough device […]
FDA approves oral multiple sclerosis treatment from J&J’s Janssen unit
Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical announced today that it received FDA approval for its Ponvory treatment. Ponvory (ponesimod) is a once-daily, oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator for treating adults with relapsing forms of multiple sclerosis (MS). It’s areas of treatment include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, […]
Oramed forms joint venture to develop oral COVID-19 vaccines with POD delivery tech
Oramed Pharmaceuticals (NSDQ:ORMP) announced today that it is forming a joint venture to develop novel oral COVID-19 vaccines. New York-based Oramed entered into definitive agreements to form Oravax Medical, which is based on Oramed’s proprietary POD (protein oral delivery) technology and Premas Biotech’s novel vaccine technology, according to a news release. Oravax’s COVID-19 vaccine candidate […]
How Lyra Therapeutics is advancing rhinosinusitis treatment
With the use of anti-inflammatory drugs constituting the standard of care for treating rhinosinusitis, Lyra Therapeutics sees an opportunity. Whatever treatments are out there for the disease in which cavities around the nasal passages are inflamed, they leave room for improvement. “We focused on chronic rhinosinusitis because it’s an area that has been ignored,” Lyra […]
UroGen Pharma raises $75M
UroGen Pharma (NSDQ:URGN) announced today that it entered into a funding agreement with RTW Investments worth $75 million. Princeton, N.J.-based UroGen’s agreement with RTW will see the biopharmaceutical company receive $75 million in upfront cash in return for tiered, future cash payments based on aggregate worldwide annual net product sales of Jelmyto (mitomycin) for pyelocalyceal […]
